(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets- Living Abroad: Social Inundation and Self-improvement
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
